NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Krispy Kreme, Inc. (NASDAQ: DNUT). Shareholders who purchased shares of DNUT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/krispy-kreme-inc-loss-submission-form/?id=155077&from=3 CLASS PERIOD: March 26, ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Designer Brands Inc. due to allegations of materially misleading business information issued to the public [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Designer Brands securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Financial Performance and Market Reaction - Designer Brands reported a soft start to 2025, citing an unpredictable macro environment and deteriorating consumer sentiment, leading to the withdrawal of its 2025 guidance [3]. - Following the announcement of these financial results, Designer Brands' stock fell by 18.2% on June 10, 2025 [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being recognized as a leader in the field [4]. - In 2019, the firm secured over $438 million for investors, and it has consistently ranked among the top firms for securities class action settlements since 2013 [4].

Core Insights - Yalla Group Limited, a social media and gaming company based in the MENA region, has seen its shares increase by 41.81% year-over-year [1] Financial Performance - The company announced its Q1 2025 financial results, which indicated revenue growth [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Designer Brands Inc. due to allegations of materially misleading business information issued by the company [1] Group 1: Company Performance - Designer Brands reported a soft start to 2025, citing an unpredictable macro environment and deteriorating consumer sentiment [3] - The company decided to withdraw its 2025 guidance amid persistent instability and pressure on consumer discretionary spending [3] - Following the announcement of these results, Designer Brands' stock fell by 18.2% on June 10, 2025 [3] Group 2: Legal Action - Shareholders who purchased Designer Brands securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] - Interested investors can join the prospective class action by submitting a form or contacting the firm directly [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [4] - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [4]

ATHENS, Greece, June 24, 2025 (GLOBE NEWSWIRE) -- EuroHoldings Ltd. (NASDAQ: EHLD) (“EuroHoldings” or the “Company”) an owner and operator of ocean-going vessels and provider of seaborne transportation, announced today that, that it will release its financial results for the first quarter ended March 31, 2025, on Wednesday, June 25, 2025, after market closes in New York. The Company will not host a conference call to discuss its results for the three-month period at this time. For any inquiries, stakeholder ...

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Diversified Holdings and Compass Group Diversified Holdings, LLC (NYSE: CODI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Compass you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/compass-diversified-holdings. Investors ...

Core Viewpoint - Addex Therapeutics reported a strong start to 2025 with significant progress in product development and business milestones, particularly in their GABAB PAM drug candidate for chronic cough and regained rights to their Phase 2 mGlu2 PAM asset, ADX71149 [2][5]. Financial Summary - Income for Q1 2025 was CHF 71,000, a decrease of CHF 164,000 from CHF 235,000 in Q1 2024 [4]. - R&D expenses decreased to CHF 156,000 from CHF 245,000, a reduction of CHF 89,000 [4][8]. - G&A expenses decreased to CHF 521,000 from CHF 778,000, a reduction of CHF 257,000 [4][8]. - Total operating loss improved to CHF 606,000 from CHF 788,000, an improvement of CHF 182,000 [4]. - Net loss from continuing operations was CHF 1,473,000, compared to CHF 735,000 in Q1 2024, an increase of CHF 738,000 [4]. - Net loss for the period decreased to CHF 1,473,000 from CHF 3,087,000, a reduction of CHF 1,614,000 [4][9]. - Basic and diluted net loss per share was CHF 0.01, down from CHF 0.03 in the same period last year [4][10]. - Cash and cash equivalents increased to CHF 2.8 million from CHF 1.6 million, an increase of CHF 1.2 million [4][11]. - Shareholders' equity improved significantly to CHF 8.3 million from a negative CHF 1.4 million [4]. Operational Highlights - The GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in multiple disease models [5][6]. - The company regained rights to its Phase 2 mGlu2 PAM asset, ADX71149 [5][6]. - Indivior successfully advanced their GABAB PAM program for substance use disorders through IND enabling studies [5][6]. - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [5][6].

Group 1 - Addex Therapeutics will release its Q1 2025 Financial Results on June 19, 2025, followed by a business update and product pipeline review during a teleconference and webcast [1][2] - The teleconference will be held at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) [2] - Addex Therapeutics focuses on developing novel small molecule allosteric modulators for neurological disorders, with its lead drug candidate, dipraglurant, under evaluation for brain injury recovery [3] Group 2 - Addex's partner, Indivior, has selected a GABAB PAM drug candidate for substance use disorders and completed IND enabling studies [3] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3] - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [3]

Core Viewpoint - Lotus Technology Inc. is set to report its unaudited financial results for the first quarter of 2025 on June 25, 2025, before the market opens in the United States [1]. Financial Reporting - The earnings conference call will take place at 8:00 AM U.S. Eastern Time on June 25, 2025, with a live audio webcast available [2]. - Participants can register for the live webcast and will receive confirmation emails with access information upon registration [2][3]. Company Overview - Lotus Technology Inc. operates in the UK, EU, and China, focusing on luxury lifestyle battery electric vehicles and next-generation automobility technologies such as electrification and digitalization [3].

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Continued progress in advancing varoglutamstat in kidney disease based on encouraging data and expansion of IP portfolioVaroglutamstat’s pre-clinical dataset showing synergistic effect in combination with an SGLT-2 inhibitor in different treatment regimensNovel composition of matter patent for varoglutamstat granted after accelerated review in the U.S.; patent term to provide exclusivity through 2044 with subsequent opportunity fo ...